C. Bethan Powell

Efficacy of Chemotherapy in <i>BRCA1/2</i> Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study

Joo Ern Ang, Charlie Gourley, C. Bethan Powell et al. · Clinical Cancer Research · 2013 · 140 citations

Medicine, Oncology, Pharmacology +16

Resistance to cytolysis by tumor necrosis factor alpha in malignant gynecological cell lines is associated with the expression of protein(s) that prevent the activation of phospholipase A2 by tumor necrosis factor alpha.

David G. Mutch, C. Bethan Powell, M.S. Kao et al. · PubMed · 1992 · 37 citations

Life Sciences, Cell Biology, Oncology +8

Feasibility and preliminary safety and efficacy of first-in-human intraperitoneal delivery of MCY-M11, anti-human-mesothelin CAR mRNA transfected into peripheral blood mononuclear cells, for ovarian cancer and malignant peritoneal mesothelioma.

Christina M. Annunziata, Armin Ghobadi, Eduardo J. Pennella et al. · Journal of Clinical Oncology · 2020 · 29 citations

Medicine, Oncology, Pharmacology +14

Dexamethasone used as an antiemetic in chemotherapy protocols inhibits natural cytotoxic (NC) cell activity

C. Bethan Powell, David G. Mutch, Ming-Shian Kao et al. · Cancer · 1990 · 16 citations · Full text

Medicine, Oncology, Pharmacology +12

Common expression of a tumor necrosis factor resistance mechanism among gynecological malignancies

C. Bethan Powell, David G. Mutch, L. Stewart Massad et al. · Cancer Immunology Immunotherapy · 1990 · 14 citations · Full text

Medicine, Gynecology, Oncology +16